A detailed history of Barclays PLC transactions in Next Cure, Inc. stock. As of the latest transaction made, Barclays PLC holds 67,518 shares of NXTC stock, worth $88,448. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67,518
Previous 67,518 -0.0%
Holding current value
$88,448
Previous $107,000 14.02%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.17 - $2.49 $35 - $74
-30 Reduced 0.04%
67,518 $107,000
Q1 2023

May 04, 2023

SELL
$1.46 - $1.83 $17 - $21
-12 Reduced 0.02%
67,548 $100,000
Q4 2022

Feb 13, 2023

SELL
$1.2 - $3.07 $634 - $1,624
-529 Reduced 0.78%
67,560 $95,000
Q2 2022

Aug 12, 2022

SELL
$3.38 - $5.27 $16,213 - $25,280
-4,797 Reduced 6.58%
68,089 $320,000
Q1 2022

May 16, 2022

BUY
$4.76 - $6.24 $4,426 - $5,803
930 Added 1.29%
72,886 $354,000
Q4 2021

Feb 14, 2022

SELL
$5.7 - $9.1 $13,731 - $21,921
-2,409 Reduced 3.24%
71,956 $432,000
Q3 2021

Nov 09, 2021

BUY
$6.74 - $8.02 $241,986 - $287,942
35,903 Added 93.35%
74,365 $501,000
Q2 2021

Aug 13, 2021

BUY
$7.6 - $10.28 $2,910 - $3,937
383 Added 1.01%
38,462 $309,000
Q1 2021

May 13, 2021

SELL
$9.81 - $13.88 $53,680 - $75,951
-5,472 Reduced 12.56%
38,079 $381,000
Q4 2020

Feb 11, 2021

SELL
$9.47 - $12.43 $27,084 - $35,549
-2,860 Reduced 6.16%
43,551 $474,000
Q3 2020

Nov 12, 2020

BUY
$8.15 - $21.17 $297,271 - $772,175
36,475 Added 367.1%
46,411 $407,000
Q2 2020

Aug 12, 2020

BUY
$21.19 - $40.2 $86,730 - $164,538
4,093 Added 70.05%
9,936 $213,000
Q1 2020

May 13, 2020

SELL
$32.32 - $58.37 $311,435 - $562,453
-9,636 Reduced 62.25%
5,843 $216,000
Q4 2019

Feb 10, 2020

BUY
$25.0 - $92.22 $340,825 - $1.26 Million
13,633 Added 738.52%
15,479 $872,000
Q3 2019

Nov 14, 2019

SELL
$15.73 - $41.6 $127,648 - $337,584
-8,115 Reduced 81.47%
1,846 $56,000
Q2 2019

Aug 14, 2019

BUY
$14.16 - $20.64 $141,047 - $205,595
9,961 New
9,961 $138,000

Others Institutions Holding NXTC

About NextCure, Inc.


  • Ticker NXTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,748,800
  • Market Cap $36.4M
  • Description
  • NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...
More about NXTC
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.